Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV Administration of Vancomycin Clear all
Terminated Phase 4 Interventional Results available

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

NCT05156437
View directory record Official record
Conditions
Endocarditis
Interventions
Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

NCT01499277
View directory record Official record
Conditions
Complicated Skin and Soft Tissue Infection
Interventions
Ceftaroline fosamil, Vancomycin, Aztreonam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Chula Vista, California • Orlando, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

NCT00428844
View directory record Official record
Conditions
Osteomyelitis
Interventions
daptomycin, vancomycin, teicoplanin, nafcillin, oxacillin, flucloxacillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
17
States / cities
Little Rock, Arkansas • Englewood, Colorado • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 17, 2026, 3:05 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01431339
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
IV Dalbavancin, Vancomycin/Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 17, 2026, 3:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)

NCT06640491
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
IO Administration of Cefazolin, IO Administration of Vancomycin, IV Administration of Cefazolin, IV Administration of Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 17, 2026, 3:05 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vancomycin in TKAs

NCT07282782
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Vancomycin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01984684
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
delafloxacin, vancomycin, aztreonam
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 17, 2026, 3:05 AM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 17, 2026, 3:05 AM EDT
Terminated Phase 1 Interventional

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

NCT01019681
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Cord blood stem cell injection
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 72 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 2 Interventional Results available

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

NCT00062647
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 17, 2026, 3:05 AM EDT
Terminated Phase 4 Interventional Results available

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

NCT01104662
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions
Vancomycin, Daptomycin, Semi-Synthetic Penicillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Azusa, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 17, 2026, 3:05 AM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?

NCT03713528
View directory record Official record
Conditions
Joint Infection
Interventions
Intraoperative Intraosseous Vancomycin
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
10
States / cities
San Francisco, California • Gainesville, Florida • Weston, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

NCT00366249
View directory record Official record
Conditions
Bacterial Infections, Diabetic Foot, Osteomyelitis
Interventions
Tigecycline, Ertapenem
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
26
States / cities
Los Angeles, California • Northridge, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 4 Interventional Results available

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

NCT01419184
View directory record Official record
Conditions
Staphylococcal Skin Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 4 Interventional Results available

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00084266
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid (Zyvox), vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
108
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 17, 2026, 3:05 AM EDT
Completed No phase listed Observational

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

NCT04317963
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Bezlotoxumab, Standard CDI treatment
Biological · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

NCT02582203
View directory record Official record
Conditions
Skin Diseases, Infectious, Staphylococcal Skin Infections
Interventions
Ceftaroline, Vancomycin
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Phase 3 Interventional

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

NCT00324922
View directory record Official record
Conditions
Osteomyelitis, Methicillin-resistant Staphylococcus Aureus
Interventions
trimethoprim-sulfamethoxazole, vancomycin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Sep 17, 2026, 3:05 AM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

NCT01401023
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile
Interventions
Tigecycline
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
East Lansing, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 17, 2026, 3:05 AM EDT